1. Controlling release from 3D printed medical devices using CLIP and drug-loaded liquid resins.
- Author
-
Bloomquist, Cameron J., Mecham, Michael B., Paradzinsky, Mark D., Janusziewicz, Rima, Warner, Samuel B., Luft, J. Christopher, Mecham, Sue J., Wang, Andrew Z., and DeSimone, Joseph M.
- Subjects
- *
CONTROLLED release drugs , *MEDICAL equipment , *THREE-dimensional printing , *DRUG delivery devices , *GUMS & resins , *INDIVIDUALIZED medicine - Abstract
Mass customization along with the ability to generate designs using medical imaging data makes 3D printing an attractive method for the fabrication of patient-tailored drug and medical devices. Herein we describe the application of Continuous Liquid Interface Production (CLIP) as a method to fabricate biocompatible and drug-loaded devices with controlled release properties, using liquid resins containing active pharmaceutical ingredients (API). In this work, we characterize how the release kinetics of a model small molecule, rhodamine B-base (RhB), are affected by device geometry, network crosslink density, and the polymer composition of polycaprolactone- and poly (ethylene glycol)-based networks. To demonstrate the applicability of using API-loaded liquid resins with CLIP, the UV stability was evaluated for a panel of clinically-relevant small molecule drugs. Finally, select formulations were tested for biocompatibility, degradation and encapsulation of docetaxel (DTXL) and dexamethasone-acetate (DexAc). Formulations were shown to be biocompatible over the course of 175 days of in vitro degradation and the clinically-relevant drugs could be encapsulated and released in a controlled fashion. This study reveals the potential of the CLIP manufacturing platform to serve as a method for the fabrication of patient-specific medical and drug-delivery devices for personalized medicine. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF